MedTrace Logo

Regional Block for Post-mastectomy Analgesia

NCT07683416 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2026-08-24

No results posted yet for this study

Summary

A large number of patients undergoing major surgical procedures for the management of breast cancer complain of acute and chronic postoperative pain. Morphine administration for acute pain after mastectomy surgery has many side effects. Regional block techniques, such as paravertebral block and thoracic epidural anaesthesia, have possible complications and technical difficulties. So, we will discuss adding dexmedetomidine as an adjuvant to bupivacaine for serratus-intercostal versus erector-spinae plane block to relieve post-mastectomy pain.

Conditions

  • Analgesia

Interventions

PROCEDURE

Serratus-intercostal plane block

The patients will receive an ultrasound-guided serratus-intercostal plane block after induction of anaesthesia, using 0.25% bupivacaine and 1 μg/kg dexmedetomidine.

PROCEDURE

Erector spinae plane block

The patients will receive an ultrasound-guided erector spinae plane block after induction of anaesthesia, using 0.25% bupivacaine and 1 μg/kg dexmedetomidine.

DRUG

Dexmedetomidine Injection

The local anaesthetic mixture will include 0.25% bupivacaine plus 1 μg/kg dexmedetomidine.

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Nahla Mohamed Amin, MD · Department of Anesthesia, Intensive Care & Pain Management, Zagazig University

  • Samia Mohamed Masoud, MD · Department of Anesthesia, Intensive Care & Pain Management, Zagazig University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2027-01-31
Completion
2027-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07683416 on ClinicalTrials.gov